Mesalamine to Reduce T Cell Activation in HIV Infection
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine whether 12 weeks of mesalamine therapy added to a
standard HIV treatment decreases systemic immune activation and inflammation in HIV-infected
patients, possibly resulting in better recovery of the immune system. The study hypothesis is
that decreasing inflammation directly in the gut may decrease both of these potential causes
of chronic inflammation, potentially resulting in an immunologic benefit.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Bausch Health Americas, Inc. California HIV/AIDS Research Program Valeant Pharmaceuticals International, Inc.